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Abstract
Background/Aim. Mesenchymal stromal cells (MSCs) have
been utilised in many clinical trials as an experimental treat-
ment in numerous clinical settings. Bone marrow remains the
traditional source tissue for MSCs but is relatively hard to ac-
cess in large volumes. Alternatively, MSCs may be derived
from other tissues including the placenta and adipose tissue.
In an initial study no obvious differences in parameters such
as cell surface phenotype, chemokine receptor display, meso-
dermal differentiation capacity or immunosuppressive ability,
were detected when we compared human marrow derived-
MSCs to human placenta-derived MSCs. The aim of this
study was to establish and evaluate a protocol and related
processes for preparation placenta-derived MSCs for early
phase clinical trials. Methods. A full-term placenta was taken
after delivery of the baby as a source of MSCs. Isolation,
seeding, incubation, cryopreservation of human placenta-
derived MSCs and used production release criteria were in ac-
cordance with the complex regulatory requirements applica-
ble to Code of Good Manufacturing Practice manufacturing
of ex vivo expanded cells. Results. We established and evalu-
ated instructions for MSCs preparation protocol and gave an
overview of the three clinical areas application. In the first
trial, MSCs were co-transplanted iv to patient receiving an al-
logeneic cord blood transplant as therapy for treatment-
refractory acute myeloid leukemia. In the second trial, MSCs
were administered iv in the treatment of idiopathic pulmonary
fibrosis and without serious adverse effects. In the third trial,
MSCs were injected directly into the site of tendon damage
using ultrasound guidance in the treatment of chronic re-
fractory tendinopathy. Conclusion. Clinical trials using both
allogeneic and autologous cells demonstrated MSCs to be
safe. A described protocol for human placenta-derived MSCs
is appropriate for use in a clinical setting, relatively inexpen-
sive and can be relatively easily adjusted to a different set of
regulatory requirements, as applicable to early phase clinical
trials.
Key words:
stromal cells; therapeutics; clinical protocols; clinical
medicine.
Apstrakt
Uvod/Cilj. Mezenhimske matiÿne (stromalne) ýelije
(MSCs) trenutno se koriste u velikom broju kliniÿkih istraži-
vanja za razliÿite kliniÿke indikacije. Iako je koštana srž uo-
biÿajeni izvor poÿetnog materijala za kultivaciju ovih ýelija,
koliÿina ýelija koja se pri tome dobija i dalje predstavlja
ograniÿavajuýi faktor. Alternativno, MSCs sve više se izoluju
iz drugih tkiva kao što su placenta novoroĀenih beba ili ma-
sno tkivo. U inicijalnom istraživanju nije otkrivena nikakva
razlika u osnovnim fenotipskim karakteristikama ýelijskih
receptora, hemokinskih receptora ili sposobnosti ýelija za
normalnu mezodermsku diferencijaciju izmeĀu MSCs izolo-
vanih iz placente i koštane srži. Cilj ovog rada bio je uspos-
tavljanje i procena protokola za kultivaciju i odabir MSCs
izolovanih iz placente i adekvatno pripremljenih za upotre-
bu u kliniÿkim istraživanjima prve faze. Metode. U ovoj
studiji korišýena je placenta beba roĀenih carskim rezom
nakon normalne trudnoýe. Izolacija, zasejavanje, inkubacija,
krioprezervacija i kriterijumi za proizvodnju humanih MSCs
bili su u skladu sa složenim regulatornim principima koji se
u ovom trenutku primenjuju u Australiji. Rezultati. Uspo-
stavljen je i procenjen detaljan protokol za pripremu MSCs i
dat je pregled njihove upotrebe u tri razliÿite kliniÿke studije.
U prvoj studiji MSCs su date iv putem, pre alogene trans-
plantacije matiÿnih ýelija krvi, u leÿenju akutne mijeloidne
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leukemije refraktorne na terapiju. U drugoj studiji, MSCs su
date iv u leÿenju idiopatske fibroze pluýa, bez ozbiljnih ne-
željenih efekata. U treýoj studiji, MSCs su injektovane di-
rektno u mesto ošteýenja tetive pod kontrolom ultrazvuka,
u leÿenju hroniÿne refraktorne tendinopatije. Zakljuÿak.
Kliniÿke studije, bazirane na primeni ýelija alogenog i auto-
lognog porekla, demonstrirale su bezbednu upotrebu MSCs.
Prikazani protokol je pogodan za rane faze kliniÿkih istraži-
vanja, relativno je pristupaÿan i može se lako prilagoditi raz-
liÿitim kliniÿkim uslovima i zakonskim regulativama.
Kljuÿne reÿi:
ýelije, stromalne; leÿenje; protokoli, kliniÿki; medicina,
kliniÿka.
Introduction
Although stem cells and their differentiated progeny of-
fer great promise for treatment of many congenital and ac-
quired human diseases, the optimal type and source remain
unclear 1, 2. Mesenchymal stromal cells (MSCs), derived
from rare mesenchymal stem cells, are fibroblastoid cells
that are present in the bone marrow and virtually all other
tissues of the body and which can be readily isolated and ex-
panded ex vivo 3–10. MSCs are able to differentiate in vitro
into cells of the mesodermal lineage such as osteoblasts,
chondrocytes and adipocytes, but their ability to differentiate
to cells outside the mesodermal lineage such as hepatocytes,
endothelial cells and neuronal cells is controversial 1, 2, 6.
MSCs are also able to modulate the activity of cells of the
immune system. Preclinical studies to date have provided a
significant amount of information on MSCs indicating that
they can deliver therapeutic proteins in a paracrine fashion or
participate in the repair of defects by mesodermal differen-
tiation 3–10. The same studies emphasize the potential of
MSCs in vivo and their capacity to home to sites of tissue
injury and inflammation. MSCs have the potential for cell
banking 5, 11. With no need to match a donor and intended re-
cipients for the antigens of the major histocompatibility
complex (MHC), MSCs from a single manufacturing cam-
paign can be utilised in numerous clinical trials and for a
number of patients 5, 11. However, MSCs manufacture is a
highly specialized, rather complex, time consuming and la-
bour-intensive exercise 11–13. The placenta is a natural “waste
product” at birth and can provide a practically unlimited
supply of donor tissue 6, 11, 12. Human placenta-derived MSCs
(also referred to as hpMSCs, in further text MSCs) need to
be isolated, cultured and cryopreserved according to strin-
gent regulatory requirements 11, 12 including the current Code
of Good Manufacturing Practice (cGMP) standard or its
close equivalent 11, 12. The manufacturing process includes
collection of source tissue (placenta), isolation of MSCs, and
their subsequent processing, storage and transport 2, 5, 11, 12, 14.
A set of policies and procedures is required to support the
manufacturing process; this process needs to be based on the
Quality Management System (QMS) principles, the Interna-
tional Organization for Standardization (ISO) standard and
other complex regulatory requirements 13–17. MSC from vari-
ous sources have been used extensively in different disease
models 18–20 and continue to be investigated for safety, efficacy
and potency 21–24, their lifespan 25 as well as manufacturing
protocol variations, improvements and adjustments 26–28.
The primary aim of this paper was to establish a proto-
col for manufacturing/ preparation of clinical-grade human
placenta-derived MSCs that could be cell banked and used
for various clinical applications on an “as needed” basis. Ad-
ditionally, we aimed to evaluate the protocol and its feasibil-
ity in a clinical trial programme, in the areas of hematology
(co-transplantation of human MSCs and allogeneic cord
blood cells as therapy for treatment-refractory hematological
malignancies), pulmonary medicine (intravenous admini-
stration of MSCs for idiopathic pulmonary fibrosis), and in a
musculoskeletal application (local administration of MSCs
for chronic refractory tendinopathies). The key parameters
for evaluation of the protocol were: 1) manufacturing con-
siderations of MSCs for use in clinical settings; 2) regulatory
considerations related to MSCs manufacturing (eg could  the
protocol be relatively easily adjusted to comply with a dif-
ferent set of regulatory requirements as mandated for appli-
cations in early phase clinical trials in Australia or other
comparable sets of regulations), and 3) safety, accessibility
and usability of human placenta-derived MSC.
Methods
The material used for cell isolation, culture and cryo-
preservation is presented in Table 1. The placenta was col-
lected from a healthy mother (the donor) during a routine
term elective Caesarean section birth 5, 6, 11. A full informed
consent was attained several weeks prior to the delivery
5, 6, 11. The donor selection guidelines of both the Australian
Red Cross Blood Services and the Australian Cord Blood
Registry (AusCord) were fulfilled 11, 14. A complex set of
quality assurance system policies was applied to each step of
the collection, processing, storage and transport of MSCs 5, 6, 11.
The placenta (Figure 1) was collected and double-
bagged aseptically in the operating suite and transferred in a
cool box to the processing laboratory 5, 6, 11. The external
membranes and the umbilical cord were removed from the
placenta in a biosafety flow-cabinet using an aseptic tech-
nique.  The placental tissue was divided into smaller pieces
(up to 10 g each) 5, 6, 11. The small pieces of placental tissue
were washed with 500 mL/100 g of Hanks Balanced Saline
Solution (HBSS, Invitrogen) 6 and this process was repeated
with the same volumes of HBSS for several times.
Additional details on MSCs isolation, seeding, incuba-
tion and cryopreservation are described in Table 2. Each pas-
sage consisting of 90 tissue culture flasks (T175) yielded
between 4 u 108 and 1 u 109 cells. At the end of each passage
(P2 to P5), cells were reseeded and also cryopreserved for
clinical trial use and further testing 6. The MSCs intended for
cryopreservation were washed with 50 mL HBSS twice,
centrifuged and the pellet was resuspended in 65% Plasma-
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Table 1
Materials used for human placenta-derived mesenchymal stromal cells isolation, culture and cryopreservation 5, 6, 11.
Equipment and solutions Media and reagents (1) Media and reagents (2)
- On-demand label printer (Birch)
- Weighing balance (Sartorius)
- Heat Sealer CRG (Ljungberg and Kogel
  AB)
- Bench Centrifuge (Sigma)
- Cryocyte Freezing bags, 50 mL (Baxter)
- Controlled-rate freezer (Planar)
- Sterile surgical gowns, face masks, over-
   shoes and hair nets (Kimberley-Clark)
- 0.2 ȝm sterile filter (Becton Dickinson)
- Incubated Orbital Shaker (Bioline)
- 70 ȝm cell strainer (BD Pharmingen)
- Centrifuge tubes, 50 mL, conical bottom
  (Nunc)
- FACS tubes (BD Pharmingen)
- Syringes (60 mL) (Terumo)
- Mixing canula (Unomedical)
- Seriological pipettes; 5, 10 and 25 mL
  (Sarstedt) and motorized pipetter.
- Tissue culture flasks (175 cm2 and 25
cm2)   (Nunc)
- Sterile 70% ethanol (Pharmacia)
- Sterile water (Baxter)
- Hanks Balanced Salt Solution   (HBSS)
(Invitrogen)
- TrypLE Select (recombinant trypsin-
  like substitute) (Invitrogen).
  Dulbecco’s Modified Eagle Medium,
  low glucose 1g/100 mL (DMEM-LG,
  Invitro gen)
- Trypan Blue (Invitro gen)
- Gentamicin, 40 mg/mL (Pharmacia)
- Ficoll-Paque Premium (GE
  Healthcare)
- Fetal calf serum, Australian sourced
  (Invitrogen)
- Digest Media: 50 mL Collagenase I
  stock (Worthington (stock is 0.2 ȝm
  filter sterilised 2000 U/mL
  colla  genases in sterile RO-grade
  water)
- Pulmozyme (recombinant cGMP
  grade DNase I) (Genentech)
- Albumex 40 (40% human serum
  al  bumin, Australian Red Cross   Blood
Service)
- Tissue culture (TC) medium (TCM):
  DMEM-LG supplemented with 20 %
  fetal bovine serum (Invitrogen) and   50
ȝg/mL gentamicin (40 mg/mL   stock)
- Bovine serum albumin
  (BSA)(Sigma)
- Plasma-Lyte 148 Replacement
  In  travenous Infusion (Baxter)
- CryoSure-Dimethyl-sulphoxide
  (DMSO) (Wak Chemie)
- Cryopreservation media: 65 mL
  Plasmalyte, 25 mL Albumex-20 and
  10 mL DMSO (Note: to avoid
  pro  tein precipitation always add
  Albumex-20 to the Plasmalyte and
  mix before adding DMSO)
- 7-Amino-actinomycin D (7AAD)
  (BD Pharmingen)
- mAbs: CD45APC-Cy7, CD73PE,
  CD105FITC CD45APC-Cy7,
  CD73PE, CD105FITC (BD
  Pharm  ingen)
- Calibrite fluorescent beads (BD
  Pharmingen)
- Sterile phosphate buffered saline
  (PBS) (Invitrogen)
Table 2
Methods used for human placenta-derived mesenchymal stromal cells isolation, cell seeding, incubation and
cryopreservation 5, 6, 11
Cell isolation Cell seeding Cell incubation and cryopreservation
- The pieces of tissue were finely diced
and transferred to 50 mL centrifuge tubes
(approximately 10 g per tube). The 16 x 50
mL tubes were used. Dulbecco’s modified
Eagle’s medium-low Glucose (DMEM-
LG; SACF Biosciences) with 100 U/mL
collagenase, type I (Worthington Bio-
chemical Corporation) and 5 ȝg/mL
DNase I (Pulmozyme) was added to each
tube up to a total volume of 25 mL.
- The cells were pelleted by centrifu-
gation (540 g, 5 min, 4°C), the super-
natant discarded and the cell pellets
resuspended in 30 mL HBSS. 12 mL
Ficoll-Paque™ Premium (1.073
g/mL) was then under-layered. Sam-
ples were centrifuged (540 g, 20°C,
20 min, no brake).
- The cells were removed by pipetting
HBSS across the monolayer. The cells were
pelleted by centrifugation (350 g, 5 min,
4°C) and cell pellets resuspended in DMEM
media. The cells were equally divided be-
tween 90 T175 flasks, each in a final volume
of 60 mL DMEM media and further incu-
bated (as above). This equated to an ap-
proximate cell concentration of 0.7–1.4 x
104/mL (in our first two production runs).
- Tubes were placed in an incubated
shaker (37°C, 2 hr), then pulse spun at
(540 g, 5 sec, 4°C)  to remove large par-
ticulate matter and the cell suspensions
were collected and filtered into  16 x 50
mL centrifuge tubes using 70 μm filters
(BD Falcon).
- The cells at the interface of were
transferred to 12 x 50 mL centrifuge
tubes, HBSS as added to 50 mL and
the cells were pelleted by centrifuga-
tion (540 g, 20°C, 10 min). The cells
were resuspended in 10 mL DMEM
media: (DMEM (1g/l glucose), 20 %
FCS (Invitrogen, cat # 10099-141,
Australian sourced), 50 ȝg/mL gen-
tamicin (Pharmacia).
- The relatively large volume of 60 mL
was used because the media was left on
the cells for 6–7 days without being
changed. When these were confluent after
approximately 6–7 days, the cells were
detached from the flasks.
- 15 mL HBSS was added to the original
tubes containing large particulate pla-
cental matter and the tubes were in-
verted several times to elute remaining
loose cells into suspension6. Tubes were
pulse centrifuged as before to pellet
large particulate matter (540 g, 5 sec,
4°C), and cell suspensions were trans-
ferred to fresh tubes through 70 μm fil-
ters.
- Cells were initially seeded into 8
T175 cm2 tissue culture flasks (T175).
The cells were cultured in 30 mL
DMEM media (37°C, 5% CO2, hu-
midified incubator). The relatively
high FCS concentration was used to
maximise cell expansion rate. When
the cells were about 90–99% conflu-
ent, the DMEM media was removed
and flasks washed with 20 mL HBSS.
5 mL TrypLE select (a GMP grade
trypsin-like substitute) (Invitrogen),
was added to each flask and incubated
(15 min, 37°C).
- The majority of cells were then cryore-
served, whilst a fraction of the cells were
used to seed a further 90 T175 flasks.
This procedure was repeated a further
three times.
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lyte (Baxter Healthcare), 25% human serum albumin (Aus-
tralian Red Cross) and 10% DMSO (Wak-Chemie Medical
GmbH). The cells were frozen either in 50 mL freezing bags
(Baxter Healthcare) or in 1.8 mL cryovials (Nunc) 6. A set of
release criteria 6 is shown in Table 3.
The osteogenic differentiation was obtained while con-
fluent MSCs were cultured for three weeks (solution:
DMEM-HG, 10% FCS, 0.1 PM dexamethasone, 50 PM L-
ascorbic acid-2-phosphate, 10 mM ȕ-glycerol phosphate diso-
dium salt pentahydrate and 0.3 mM sodium phosphate) 2, 5, 6, 11.
It was assessed by staining cells in wells with Alizarin Red
S 6.  The chondrogenic differentiation was also obtained and
the cells (5 u 105 MSCs) were cultured over a 3-week period
(solution: DMEM-HG, 0.1 PM dexamethasone, 1 mM so-
dium pyruvate, 50 PM L-ascorbic acid-2-phosphate, 35 mM
L-proline, 10 ng/mL TGFE1 (R&D Systems) and 50 mg/mL
ITS Premix (insulin, human transferrin and selenious acid;
BD Biosciences) 6. Chondrogenic differentiation was evalu-
ated by staining the cell pellets with periodic acid Schiff
(PAS) 6.
Adipogenic differentiation was initiated and confluent
MSCs were cultured for three weeks (solution: DMEM-HG,
1 PM dexamethasone, 5 ȝg/mL insulin, 60 PM indomethacin
and 0.5 mM 3-Isobutyl-1-methylxanthine, IBMX) 6. Level of
the adipogenic differentiation was measured as cells were
stained with Oil Red O 6. Reagents used for differentiation
techniques were mostly obtained from Sigma 6 while mAb
were manufactured by BD Pharmingen and prepared in PBS
with 2% Human Serum Albumin (1 : 5 dilution) 6.
MSCs were detached from flasks using TrypLE select
(Life Sciences), washed and added to FACS tubes in order
to prepare them for flow cytometry analysis 6. MSC were
incubated as follows: 1 u 106 cells in 100 PL of mAb mix
(15 min at 4ºC) with directly conjugated mouse anti-human
CD45-FITC, CD14-APC-Cy7, CD73-PE and CD105-APC
antibodies 6. An additional tube with MSC was prepared
and it was stained with 5 Pg/mL isotype control mAb
(IgG1 FITC, IgG1 PE, IgG1 APC and IgG1 APC-Cy7) 6.
The excess antibody was removed and cells washed with
the phosphate buffered saline (PBS). After the last wash,
cells were resuspended in the solution consisting of 200 PL
PBS and 7-Amino-actinomycin D(7AAD) (BD Pharmin-
gen) (1 : 40 dilution) in order to exclude the dead cells. An
LSRII flow cytometer (Becton Dickinson) was used and the
data were analysed by FCS Express Version 3 software
(DeNovo) 6. A defined threshold for fulfilling our MSCs
purity criterion was set (> 85% CD73+/CD105+(double
positive), < 1% CD45+) 5, 6, 11.
(A)  (B)
Fig. 1 – The human term placenta. (A) The fetal portion of the human placenta with the umbilical cord still attached.
Mechanical separation of the fetal membranes, the amniotic membrane and the chorionic membrane is shown; (B) The
portion of the placenta that embeds into the mother’s uterus, the decidua.
/Reproduced with permission from Heazlewood et al. 14/.
Table 3
The production release criteria used for manufacturing human placenta-derived mesenchymal stromal cells 5, 6, 11, 14
Test Pre-donation Passage  0 Passage  1 Passage  2 Passage  3 Passage  4 Passage  5 Day  180**
Gram Stain N/A N/A N/A 䘟 䘟 䘟 䘟 N/A
14 day microbiological culture N/A N/A N/A 䘟 䘟 䘟 䘟 N/A
Mycoplasma detection N/A N/A N/A 䘟 䘟 䘟 䘟 N/A
Endotoxin detection N/A N/A N/A 䘟 䘟 䘟 䘟 N/A
Purity (by FACS phenotype) N/A N/A N/A 䘟 䘟 䘟 䘟 N/A
Karyotype (by cytoge-
netic analysis) N/A N/A N/A 䘟 䘟 䘟 䘟 N/A
Donor serology* 䘟 N/A N/A N/A N/A N/A N/A 䘟
Donor health questionnaire 䘟 N/A N/A N/A N/A N/A N/A 䘟
* For infectious disease markers; ** Donor/mother and the baby follow-up; 䘟– applicable; N/A – not applicable.
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Results
Establishing the protocol
Manufactured human placenta-derived MSCs were very
similar to human bone marrow-derived MSCs (hbmMSCs)
2, 5, 6. We were unable to find major differences between hu-
man placenta-derived MSCs and bone marrow-derived
MSCs in terms of morphology (Figure 2) and cell surface
phenotype 2, 5, 6 (Figure 3),  chemokine receptor display 4,
mesodermal differentiation 2, or immunosuppressive capacity
on alloreactive T cells 29. Yen et al. 17 established in their
study that human placenta-derived MSCs expressed the early
antigens SSEA4, Tra1-60 and Tra1-81, while the bone mar-
row derived MSCs lacked those antigens 6. Conversely, we
discovered a low level expression of SSEA4 and Tra1-60 on
the human placenta-derived MSCs from our manufacturing
process 4, 6.
All release from manufacturing criteria were fulfilled at
the time of passage cryopreservation 5, 6, 11 as presented in
Table 3, including pre-donation serology screening, donor
serology for infectious disease markers screening on day
180, pre-donation health questionnaire for the mother, and
the day 180 health questionnaire for the mother and the
baby 5, 6, 11, 14.
Evaluation of the protocol
Human placenta-derived MSCs manufactured at the
Mater Medical Research Institute were used for three phases
I (safety) clinical trials. These are briefly presented below.
First trial was a phase I multicentre open label dose-
escalation study of unrelated, MHCs unmatched placenta-
derived MSCs in recipients of unrelated umbilical cord blood
hematopoietic stem cell transplants.
(A) (B) (C)
Fig. 3 – The flow cytometric phenotype of human-placenta
derived mesenchymal stromal cells (MSCs) during
isolation and passaging. (A) CD45+ frequency at each
passage; (B) CD73+/CD105+ frequency at each passage;
(C) CD14+/CD45+ frequency at early passage.
/Reproduced with permission from Brooke G, et al. 6/.
In this phase I trial of safety and feasibility initiated in
2007 we co-transplanted human MSCs in a subject receiving
an allogeneic cord blood transplant as therapy for treatment-
refractory hematological malignancy. The trial was per-
formed in collaboration with Professors Ken Bradstock and
David Gottlieb of Westmead Hospital, Sydney. MSCs at a
dose of 1 u 106 MSCs/kg were infused into the cord blood
recipient 5 hours before infusion of cord blood cells 6, in or-
der to obtain a 5-hour window for observation of early ad-
verse reactions due to MSCs (for example, infusional toxic-
ity) unclouded by any possible side-effects from subsequent
infusion of cord blood cells. The time from submission of the
application until approval was received from the two institu-
tional Human Research Ethics Committee (HRECs) involved
was one year in total 6. Two-way clinical trial agreements
were put in place with an appropriate indemnification for
each of the participating sites and for any adverse events at-
tributed to MSCs. During this time, a request was made by
one of the institutional HRECs for an external audit to be
Fig. 2 – Photomicrograph showing morphology (Giemsa stain
and Phalloidin stain) and mesodermal differentiation of hu-
man placenta-derived mesenchymal stromal cells (MSC). (A)
Giemsa stain of human placenta-derived MSCs; (B) Morphol-
ogy of human placenta-derived MSCs when stained with
Phalloidin-AF546; (C) Osteogenic (i), chondrogenic (ii) and
adipogenic (iii) differentiation and histological staining of hu-
man placenta-derived MSCs by alizarin red, Periodic acid
schiff and Oil Red O, respectively.
Original magnification x1000 (A); u400 (B) and (Ciii); u100 (Ci) and
(Cii).
/Reproduced with permission from Brooke G, et al. 6/.
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conducted in the manufacturing processes outlined in the
study protocol. This was performed by the staff of the Aus-
tralian Red Cross Blood Service. We have conducted the two
were external audits since then.
Clinical course 6: 24 hours after the pre-transplant
myeloablative conditioning regimen completion (cyclophos-
phamide plus a total body irradiation), 100 u 106 human pla-
cental MSCs (1 u 106/kg) were given intravenously to a 20-
year-old Caucasian male with acute myeloid leukaemia in
second remission 6. The cells were suspended in 30 mL and
were infused over 7 min using a 200 ȝm in-line filter. No ad-
verse events were noted. According to the study protocol, the
patient received two allogeneic cord blood units five hours
later. The total nucleated cell dose from two cord blood units
was, post-thaw, 3.6 u 107/kg while the total CD34+ cell dose
was 1.2 u 105/kg 6. The placenta-derived MSCs given to the
patient were MHC-unmatched with both the recipient and the
two cord units 6. MSCs donors and cord blood donors were
unrelated to each other 6. At the day 70 posttransplant the
patient developed cytomegalovirus (CMV) infection and he
subsequently died from multiorgan failure 6. Of note, MSCs
had been procured from a CMV-seronegative maternal do-
nor. There were no reported serious adverse events related to
the MSCs, including infusional toxicity or ectopic tissue
formation. This trial was ceased when Westmead Hospital
decided to no longer perform cord blood transplants in adult
subjects. This was the first time, to our knowledge, that pla-
centa-derived MSCs have been trialled in humans 6, 11.
Second trial was a phase I study to evaluate the poten-
tial role of MSCs in treatment of idiopathic pulmonary fibro-
sis.
In 2010 we initiated a phase I trial of MSCs in col-
laboration with Drs Daniel Chambers and Peter Hopkins of
the Prince Charles Hospital in Brisbane. Idiopathic pulmo-
nary fibrosis is a chronic, fibrosing lung disease of un-
known cause predominantly occurring in middle-aged peo-
ple that is characterized by severe, refractory and progres-
sive breathlessness. There is no effective treatment for this
disease except for lung transplantation, and this approach is
limited by a shortage of lung organ donors. The rationale
for this trial was based on literature reports of a beneficial
effect noted in mice given murine MSCs after experimental
pulmonary fibrosis was induced by the cytotoxic drug
bleomycin.
Clinical course: MSCs were administered iv as follows:
1 u 106 MSCs/kg (first cohort of 4 subjects) and 2 u 106
MSCs/kg (second cohort of 4 subjects). A validated dry
shipper was used to transport MSCs to the collaborating hos-
pital. The cells were kept cryopreserved until required for
administration to subjects in the trial. Subsequently, the cells
were thawed and infused intravenously. There were no re-
ported serious adverse events related to MSCs, including in-
fusional toxicity or ectopic tissue formation. The results of
this trial were of interest since it involved subjects with im-
paired pulmonary function. MSCs injected intravenously
immediately home to the lungs where they remained for ap-
proximately three days and could theoretically cause further
pulmonary function compromise. This did not happen.
Third trial was a phase I study to evaluate the potential
role of MSCs in treatment of chronic refractory tendinopa-
thy.
In 2011 the phase I was initiated in subjects with
Achilles tendinopathy refractory to conventional treatments.
In contrast to the first two trials MSCs were injected directly
into the site of tendon damage using ultrasound guidance.
The Principal Investigator on this trial was Dr Mark Young,
Visiting Medical Officer in Sports Medicine at Mater Private
Hospital, Brisbane. Tendinopathy is a common condition as-
sociated with pain and diminished function in tendons. It oc-
curs in active young people, and the incidence increases with
age. The incidence of tendinopathy increases along with the
life expectancy, which in turn places larger costs on the
health system. The initial management of all tendinopathies
is conservative, including activity modification, medications,
corticosteroid injections and/or exercises. Surgical treatments
are considered if a prolonged conservative management fails,
but these interventions are costly and involve periods of im-
mobilisation.
Clinical course: All the patients received their iv MSCs
injections under the ultrasound guidance. The subjects were
monitored for a period of at least 4 weeks before the next
patient is treated so that any early adverse effects from the
previous MSCs application could be assessed – both clini-
cally and by ultrasound examination. The 3 patients of the
first cohort received a single dose of 1.0 u 106 placenta-
derived MSCs (1 mL of solution with a total of 1.0 u 106
cells per mL) each. The next cohort of 3 patients received a
total of 4.0 u 106 MSC (1.0 mL of a solution with a total of
4.0 u 106 cells per mL) each.
Each of the above trials was subjected to oversight by a
Data Safety Monitoring Committee. The Data Safety Moni-
toring Committee carried out an interim safety analysis after
each cohort of patients had received their injections and no
adverse events attributed to MSCs administration were
noted. The overall safety outcomes were encouraging since
these phase I trials were not designed to assess efficacy of
the biologic drug but its safety. Clinical trial design and
clinical outcomes (other than safety), patient inclusion and
exclusion criteria, patient follow-up, relevant controls and
clinical parameters are beyond the scope of this paper.
Discussion
In this study we presented our experience in establish-
ing a protocol for manufacturing/ preparation of clinical-
grade human placenta-derived MSCs that can be cell banked
and used for various clinical applications on an “as needed”
basis. We also evaluated the protocol based on manufactur-
ing considerations of MSCs for use in clinical settings,
regulatory considerations related to MSCs manufacturing (eg
could  the protocol  be relatively easily adjusted to comply
with a different set of regulatory requirements as mandated
for applications in early phase clinical trials in Australia or
other comparable sets of regulations), and safety, accessibil-
ity and usability of human placenta-derived MSCs. There are
several issues to be discussed.
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Firstly, there are manufacturing protocol considerations.
These include, but are not limited to, the amount and type of
tissue used as a source of cells, choice of manufacturing rea-
gents (eg clinical grade reagents) and variations of the labo-
ratory protocol, as well as the conditions of the ex vivo cell
expansion procedure (eg “open” vs “closed” system). In our
first manufacturing campaign, we used a part (300–500 g) of
one placenta (placenta 1). This represented over a half of the
total placenta mass and was used to seed 6 u T175 flasks
(P0) 6. It yielded approximately 40 u 106 cells at first passage
(P1) 6 which were then split between 90 flasks at 4.38 u 105
cells/flask and plated at the initial density of 2500 cells/cm2.
The average yield for each subsequent passage was 742 u
106 cells (with a standard deviation of 82.6 u 106) 6. At each
passage, 40 u 106 cells were held back for the next passage
and seeded to a new set of flasks at 4.38 u 105 cells/T175,
and the remaining cells were cryopreserved 6. It was noted
that cell recovery at P4 and P5 of the first processed placenta
was only 60% although cell recoveries were generally ex-
cellent 6. The noted variability may have been due to the use
of small aliquots of cells stored in cryovials for counting
purposes and testing only 5, 6. The yield from cryovials, in
our experience, tends to be slightly lower than that from
cryobags 6. The placentas (1 and 2) processed in the first two
manufacturing campaigns using clinical grade manufacturing
protocols yielded a total of 4.5 u 109 cryopreserved cells.
MSC were released from production 11 as 97% viable, Gram
stain negative, endotoxin test < 2 EU/mL, sterile on 14 day
microbiological culture, with an appropriate cell surface
phenotype CD45- and > 85% CD73+/CD105+ (eg in P2 the
results of cell purity were: 0.4% CD45+, 95 % CD73+/
CD105+; in P3: 0.0% CD45+, 99%CD73+/CD105+; in P4:
0.0% CD45+, 91% CD73+/CD105+; and in P5: 0.0% CD45+,
96% CD73+/CD105+) demonstrated by flow cytometry, and
with normal karyotype 5, 6, 11.
A two-stage release process was applied with a set of
criteria for each stage. Release from manufacturing included
tests performed on each batch of cells immediately following
manufacturing of each passage (eg sterility, mycoplasma and
endotoxin test, purity, viability, maintenance of normal
karyotype). Release from cryopreservation included tests
performed on a cryovial corresponding to each bag planned
for administration to a patient; the test-vials were thawed
several weeks before the planned administration to a patient
and sterility, viability and mycoplasma tests were performed.
In both first two manufacturing campaigns, a collage-
nase I based tissue digestion protocol was utilised. One of
the major obstacles in the initial phase of MSCs manufac-
turing was a lack of cGMP grade reagents or clinical-grade
reagents in the cell isolation steps 6. Hence, the human re-
combinant DNase was used for digestion in our manufactur-
ing process, which was produced by Roche under the cGMP
conditions. It is intended for clinical use in cystic fibrosis
treatment 6, 11.
Additionally in both our first two manufacturing cam-
paigns the cell preparation (following tissue dissociation and
digestion) was initially purified using density gradient cen-
trifugation with Ficoll-Paque Premium™ (GE Healthcare).
This is an alternative to Percoll and it is a clinical-grade rea-
gent 6, 11.
Use of media with fetal calf serum for cell expansion
may increase the theoretical risk of bovine spongiform en-
cephalitis transmission. The Australian regulatory body for
medicines, the Therapeutic Goods Administration, (TGA,
equivalent of the Food and Drug Administration [FDA] in
the USA and the European Medicine Agency [EMA] in
Europe 15) approves in principal the use of fetal calf serum in
clinical grade material production – as long as it is sourced
from a country free of bovine spongiform encephalitis, such
as Australia or New Zealand 6, 11. Most of the protocols use
10–20% fatal calf serum (FSC) growth media 24–28 but se-
rum-free media is a preferred option from the safety per-
spective.
At this stage our process of MSCs manufacture is still
conducted in an “open” system due to the multiple steps re-
quired in MSCs extraction and culture. The extended period
of cell expansion (up to 6 weeks) introduces the risk of mi-
crobial contamination although class II biosafety cabinets
and/or clean rooms are utilised, 6, 11. Hence, an extensive in-
process and end-product testings are utilised prior to release
of the cell product for clinical use 6, 11.
Secondly, there is consideration of regulatory require-
ments related to MSCs manufacturing for use in early stage
clinical trials. All stages of the manufacturing process were
completed in accordance with cGMP principles and internal
Quality Management System policies and procedures. A
Quality Management System  includes cGMP (or equivalent
standard)-compliant policies, procedures and extensive
documentation applies, but is not limited, to the following:
facilities, equipment, materials, staff, monitoring, validation,
process change, record generating and record keeping 5, 6.
Production scientists had to work closely with the regulatory
compliance staff to ensure a safe cellular therapy prod-
uct 11, 13, 14. Staff education and ongoing training were crucial
components of regulatory compliance. Overall, biologic
drugs (also referred to as biologics, biologicals or Advanced
Therapy Medicinal Products) regulations have been widely
developed by mature regulatory agencies such as the Austra-
lian framework administered by the TGA, the European
Union’s EMA levied framework and the framework of the
United States of America (USA) imposed by the FDA 15. All
of these biologic drugs regulations are multilayered and
complex 15, 16.  However, common underlying principles of
cGMP, provide a useful guide in each regulatory domain ap-
plicable to biologic drugs, including cell and tissue based
therapeutics 15, 16.
Finally, there are considerations related to the safety,
accessibility and usability of human placenta-derived MSCs.
Adult MSCs can be derived from different source-tissues and
can be expanded in culture while maintaining their charac-
teristics. MSCs are currently extensively used in preclinical
and clinical studies, including tissue engineering. There is a
considerable promise for the use of MSCs in rebuilding
damaged or diseased mesenchymal tissues in different tissue-
engineered models 8–10. The fact that MSCs secrete a large
spectrum of bioactive molecules was intriguing 10. The im-
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munosuppressive molecules produced by MSCs, especially
those affecting the T-cell immune response, are now consid-
ered to be one of the mechanisms by which MSC mediate
their therapeutic effect in some disease settings 18–23. MSC-
secreted bioactive molecules may be able to provide a regen-
erative microenvironment for a variety of injured adult tis-
sues and limit the area of tissue damage 10. Hence, a number
of clinical trials currently use allogeneic MSCs for the treat-
ment of Crohn's disease, myocardial infarcts, graft-versus-
host disease, cartilage and meniscus repair, spinal cord in-
jury, stroke and other clinical indications 18–23.
The placenta and other pregnancy-related tissues appear
an attractive source of MSCs 7, 11–14, 17, 21, 25, 28. Cells can be
prepared in advance, for a number of patients or clinical tri-
als, on a therapeutic scale manufacturing and cell banking
process. Placenta, for example, is normally discarded after
the birth of the baby, thus providing a practically unlimited
supply of source material. Placental MSCs exhibit the classi-
cal MSCs surface phenotype, differentiation potential and
have potent immunosuppressive properties 2, 6, 14, 17 . Placen-
tal MSCs have been utilised by a number of other research
groups worldwide 12.
Conclusion
Clinical trials using both allogeneic and autologous
cells have demonstrated MSCs to be safe and have targeted
diseases in areas such as orthopaedic, cardiovascular, degen-
erative and inflammatory diseases. Phase I clinical trials are
a challenging step in this process due to limited funding, la-
borious and long manufacturing procedures and the need for
a multidisciplinary team with a unique skill set. We de-
scribed a manufacturing protocol for human placenta-derived
MSCs that is appropriate for use in a clinical setting, rela-
tively inexpensive and can be relatively easily adjusted to a
different set of regulatory requirements, as applicable to
early phase clinical trials.
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